The Progressive Familial Intrahepatic Cholestasis drugs in development market research report provides comprehensive information on the therapeutics under development for Progressive Familial Intrahepatic Cholestasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Progressive Familial Intrahepatic Cholestasis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Progressive Familial Intrahepatic Cholestasis and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Progressive Familial Intrahepatic Cholestasis by nine companies/universities/institutes. The top development phase for Progressive Familial Intrahepatic Cholestasis is preclinical with six drugs in that stage. The Progressive Familial Intrahepatic Cholestasis pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Progressive Familial Intrahepatic Cholestasis pipeline products market are: Vivet Therapeutics, Qing Bile Therapeutics and Jadeite Medicines.
The key targets in the Progressive Familial Intrahepatic Cholestasis pipeline products market include Bile Salt Export Pump (ATP Binding Cassette Sub Family B Member 11 or ABCB11), Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2), and Phosphatidylcholine Translocator ABCB4 (ATP Binding Cassette Sub Family B Member 4 or Multidrug Resistance Protein 3 or P Glycoprotein 3 or MDR3 or ABCB4 or EC 7.6.2.2).
The key mechanisms of action in the Progressive Familial Intrahepatic Cholestasis pipeline product include Bile Salt Export Pump (ATP Binding Cassette Sub Family B Member 11 or ABCB11) Inhibitor with two drugs in Preclinical. The Progressive Familial Intrahepatic Cholestasis pipeline products include one routes of administration with the top ROA being Oral and two key molecule types in the Progressive Familial Intrahepatic Cholestasis pipeline products market including Small Molecule, and Gene Therapy.
Progressive Familial Intrahepatic Cholestasis overview
Progressive familial intrahepatic cholestasis (PFIC) are a group of conditions in which liver cells do not release a digestive fluid, called bile, properly. This leads to a build-up of bile inside the liver cell, known as cholestasis. Cholestasis can damage the liver. The liver cells can start to die and become replaced with scar tissue. This leads to cirrhosis (severe scarring of the liver) which can cause a number of different problems
For a complete picture of Progressive Familial Intrahepatic Cholestasis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
